Forbion leads 40m financing in Inflazome Ltd
Inflammosome inhibitor specialist Inflazome Ltd has raised 40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Boehringer and Epizyme enter US$300m deal
/in News/by Thomas GabrielczykBoehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
Breakthrough in restless legs syndrome
/in News/by Thomas GabrielczykResearchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.
SOBI and AstraZeneca in US$2bn+ deal on RSV antibodies
/in News/by Thomas GabrielczykAstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish Orphan Biovitrum […]
Antibiotic resistance spreading across Europe
/in News/by Thomas GabrielczykAntimicrobial resistance (AMR) has increased by 32% since 2007 in Europe, according to a brand new report.
Liquid biopsy: size matters
/in News/by Thomas GabrielczykA new method developed by Swiss, Danish and British researchers allows to detect hard-to-trace tumour-derived DNA in the blood (or ctDNA).
Themis postpones IPO
/in News/by Thomas GabrielczykOne week after Austrian vaccine and cancer immunotherapy specialist Bioscience announced the terms of its initial public offering (IPO) and listing on Euronext Amsterdam, the company has postponed its IPO.
New checkpoint inhibitor on the block
/in News/by Thomas GabrielczykResearchers at Austrian IMBA have identified a well-known co-factor of amino acid synthesis and monoamine neurotransmitter synthesis to play a prominent role in the development of autoimmunity and cancer.
BIO-Europe: advanced therapies in focus
/in News/by Thomas GabrielczykGene and cell therapies, pediatric drugs, and formulation were just some hot topics discussed in a record number of B2B meetings at BIO-Europe in Copenhagen.
Dry AMD: Oxurion licences heparanase blockers from Beta Therapeutics
/in News/by Thomas GabrielczykOxurion NV and Beta Therapeutics Inc have inked an R&D agreement aimed to develop new heparanase inhibitors to treat dry AMD.